7 Analysts Have This to Say About Arcutis Biotherapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Arcutis Biotherapeutics (NASDAQ:ARQT) received 7 bullish ratings from analysts, with an average 12-month price target of $38.14, a decrease of 30.65% from the previous average price target of $55.00.
August 10, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arcutis Biotherapeutics received 7 bullish ratings from analysts in the last quarter, with a lower average 12-month price target.
The company received 7 bullish ratings from analysts, indicating a positive outlook. However, the average 12-month price target has decreased by 30.65%, which could indicate a potential downside in the future. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100